Midostaurin
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Systemic Mastocytosis, Aggressive (ASM)
Conditions
Systemic Mastocytosis, Aggressive (ASM), Leukemia, Mast Cell, Hematological Non-mast Cell Lineage Disease (AHNMD)
Trial Timeline
Mar 1, 2005 → Apr 16, 2011
NCT ID
NCT00233454About Midostaurin
Midostaurin is a phase 2 stage product being developed by Novartis for Systemic Mastocytosis, Aggressive (ASM). The current trial status is completed. This product is registered under clinical trial identifier NCT00233454. Target conditions include Systemic Mastocytosis, Aggressive (ASM), Leukemia, Mast Cell, Hematological Non-mast Cell Lineage Disease (AHNMD).
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (7)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03114228 | Pre-clinical | Completed |
| NCT05219266 | Pre-clinical | Completed |
| NCT02624570 | Pre-clinical | Completed |
| NCT05488613 | Pre-clinical | Completed |
| NCT01883362 | Phase 2 | Completed |
| NCT00866281 | Phase 1/2 | Terminated |
| NCT00233454 | Phase 2 | Completed |
Competing Products
20 competing products in Systemic Mastocytosis, Aggressive (ASM)
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Tabalumab Auto-Injector + Tabalumab Prefilled Syringe | Eli Lilly | Phase 3 | 77 |
| Baricitinib + Placebo | Eli Lilly | Phase 2 | 52 |
| MRA(Tocilizumab) + placebo | Chugai Pharmaceutical | Phase 3 | 77 |
| MRA(Tocilizumab) | Chugai Pharmaceutical | Phase 3 | 77 |
| MRA(Tocilizumab) | Chugai Pharmaceutical | Phase 3 | 77 |
| DS-7011a + Placebo | Daiichi Sankyo | Phase 1 | 33 |
| DS-7011a + Placebo | Daiichi Sankyo | Phase 1/2 | 41 |
| Bocidelpar + Placebo | Astellas Pharma | Phase 1 | 33 |
| Parenteral micafungin application + Other parenteral antifungal drugs | Astellas Pharma | Pre-clinical | 23 |
| Micafungin | Astellas Pharma | Phase 2 | 52 |
| E6742 | Eisai | Phase 1/2 | 41 |
| KHK4827 | Kyowa Kirin | Phase 1 | 33 |
| KHK4827 + Placebo | Kyowa Kirin | Phase 3 | 77 |
| Baricitinib + Placebo | Eli Lilly | Phase 3 | 77 |
| Baricitinib + Cyclophosphamide | Eli Lilly | Approved | 85 |
| Baricitinib + Placebo | Eli Lilly | Phase 3 | 77 |
| LY2127399 + Placebo every 2 weeks + Placebo every 4 weeks + Standard of Care | Eli Lilly | Phase 3 | 77 |
| LY3361237 + Placebo | Eli Lilly | Phase 2 | 52 |
| LY2127399 + Placebo | Eli Lilly | Phase 3 | 77 |
| LY3361237 + Placebo | Eli Lilly | Phase 1 | 33 |